Tianjin Zhong Xin Pharmaceutical Group Corporation has recorded earnings of RMB661.7 million ($135.8 million) or 0.86 RMB cents per share for the FY2020 ended December, 6% higher than earnings of RMB625.6 million a year ago.

FY2020 revenue fell 6% y-o-y to RMB6.60 billion largely due to lower revenue brought in by the group’s Chinese medicine segment.

Gross profit for the year fell by some 13% y-o-y to RMB2.52 billion. Gross profit margin fell three percentage points to 38% in the same period.


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook